id,trial_id,criterion_type,criterion_text,is_required,parsed_json,created_at,updated_at,category,tags
224,10,inclusion,"Subjects must: 1. Be willing and able to provide voluntary written informed consent and written authorization for use and disclosure of protected health information. • In the case of pediatric subjects, a parent or legally authorized representative (LAR) must provide written informed consent and sign the health information disclosure form. The child’s assent should also be obtained as required by the overseeing Institutional Review Board (IRB).",f,,2025-07-25 16:21:05.142681,2025-07-28 19:38:47.735609,laboratory,
225,10,inclusion,"2. Be able and willing to fully comply with study procedures and restrictions. • For pediatric subjects, this requirement applies to the parent or LAR.",f,,2025-07-25 16:21:05.192329,2025-07-28 19:38:48.020665,study_procedures,
226,10,inclusion,"3. If a woman of childbearing potential (WOCBP), have a negative urine pregnancy test (UPT) at Visit 1 and be willing to use approved contraception for the duration of the study. If a sexually active adult male with a female partner of childbearing potential, be willing to use approved contraception for the duration of the study. • Non-childbearing potential is defined as a female who is either premenarchal, postmenopausal (no menstrual periods for at least 12 consecutive months without another medical cause), or has undergone documented permanent sterilization, such as a bilateral oophorectomy, hysterectomy, or tubal ligation. • Approved forms of contraception include hormonal (i.e., oral, transdermal, implant, or injection); barrier (i.e., condom or diaphragm with spermicide); intrauterine device; vasectomized partner (6 months minimum); and abstinence.",f,,2025-07-25 16:21:05.229567,2025-07-28 19:38:47.879142,demographics,
227,10,inclusion,"4. At Visit 1, have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye, confirmed by the presence of the following minimal clinical signs and symptoms in that same eye: a. Clinical observation or solicited subject report of purulent or mucopurulent ocular discharge b. Grade ≥ 1 on the modified VBR conjunctival redness scale",f,,2025-07-25 16:21:05.270849,2025-07-28 19:38:47.805461,laboratory,
228,10,inclusion,"5. Have received no ocular treatment for conjunctivitis, aside from eyelid hygiene, ≤14 days prior to Visit 1.",t,,2025-07-25 16:21:05.30943,2025-07-28 19:39:02.02258,disease_specific,
229,10,inclusion,"6. Have a negative viral conjunctivitis (e.g., QuickVue® Adenoviral Conjunctivitis Test) test in both eyes ≤24 hours prior to Visit 1 or at Visit 1.",f,,2025-07-25 16:21:05.351141,2025-07-28 19:38:47.947424,disease_specific,
230,10,inclusion,7. Be willing to discontinue use of cosmetics on the eyelids and eyelashes for the duration of the study.,f,,2025-07-25 16:21:05.396645,2025-07-28 19:38:48.105005,study_procedures,
231,10,inclusion,8. Be willing to discontinue use of contact lenses for the duration of the study.,f,,2025-07-25 16:21:05.443852,2025-07-28 19:38:48.24668,study_procedures,
232,10,exclusion,Subjects must not: 1. Be currently pregnant or lactating (WOCBP).,f,,2025-07-25 16:21:05.480703,2025-07-28 19:38:47.595176,reproductive,
233,10,exclusion,2. Have participated in another clinical trial ≤30 days prior to Visit 1.,f,,2025-07-25 16:21:05.519072,2025-07-28 19:38:48.179072,medical_history,
234,10,exclusion,3. Have received another experimental drug ≤90 days prior to Visit 1.,f,,2025-07-25 16:21:05.566629,2025-07-28 19:38:48.600869,medical_history,
235,10,exclusion,4. Have a household member enrolled in this study.,f,,2025-07-25 16:21:05.607297,2025-07-28 19:38:48.31738,study_procedures,
236,10,exclusion,"5. Have any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence of active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone marrow transplant.",t,,2025-07-25 16:21:05.658129,2025-07-28 19:39:32.697004,disease_specific,
237,10,exclusion,6. Be blind or have monocular vision.,f,,2025-07-25 16:21:05.697996,2025-07-28 19:38:48.385461,general,
238,10,exclusion,"7. Have a current or recurrent ocular or systemic disease that could affect study conduct, clinical or laboratory assessments, or the action, absorption, or disposition of the investigational product (IP), per the Investigator’s discretion.",f,,2025-07-25 16:21:05.739294,2025-07-28 19:38:48.531215,laboratory,
239,10,exclusion,8. Have experienced signs and symptoms of bacterial conjunctivitis for >48 hours prior to Visit 1.,t,,2025-07-25 16:21:05.777203,2025-07-28 19:39:38.123478,laboratory,
240,10,exclusion,9. Have a known hypersensitivity to or intolerance of benzalkonium chloride or other components of Fucithalmic or placebo.,f,,2025-07-25 16:21:05.814336,2025-07-28 19:38:48.807013,general,
241,10,exclusion,"10. Have had a diagnosis of or clinical presentation consistent with non-infectious conjunctivitis or non-bacterial ocular infection (e.g., viral, fungal, acanthamoeba, or other parasitic) ≤30 days prior to Visit 1. • History of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is not exclusionary.",f,,2025-07-25 16:21:05.852794,2025-07-28 19:38:49.109074,laboratory,
242,10,exclusion,"11. Have and/or report any of the following at Visit 1: a. Trauma to the eye <3 months prior to Visit 1 or any history of ocular trauma that may affect study outcomes, in the opinion of the Investigator b. Photophobia in conjunction with severe ocular pain c. Blurred vision not cleared by rapid blinking d. Tender eye upon palpation e. Unequal and/or poorly reacting pupil, in the opinion of the Investigator f. White opacity on the cornea",f,,2025-07-25 16:21:05.891348,2025-07-28 19:38:49.034711,medical_history,
243,10,exclusion,12. Have nasolacrimal duct obstruction or punctal plugs at Visit 1.,f,,2025-07-25 16:21:05.931972,2025-07-28 19:38:48.736914,study_procedures,
244,10,exclusion,13. Have had ocular surgical intervention ≤6 months prior to Visit 1 or plans for such intervention during the study period.,f,,2025-07-25 16:21:05.968736,2025-07-28 19:38:48.882868,medical_history,
245,10,exclusion,"14. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome.",f,,2025-07-25 16:21:06.005552,2025-07-28 19:38:48.955366,disease_specific,
246,10,exclusion,15. Have an active case or a history of ocular herpes.,f,,2025-07-25 16:21:06.045494,2025-07-28 19:38:49.246174,medical_history,
247,10,exclusion,"16. Have used any of the following treatments within the specified timeframe. Use during the study is also prohibited. a. Cyclosporine eye drops ≤7 days prior to Visit 1 b. Ocular, periocular, or systemic antibiotics ≤14 days prior to Visit 1. At Visit 1, systemic antibiotic use may be permitted if deemed by the Investigator to be clinically necessary to treat a sexually transmitted disease. c. Ocular, periocular, or systemic corticosteroids ≤14 days prior to Visit 1. Stable use (initiated ≥30 days prior to Visit 1) of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the periocular area. d. Topical or systemic non-steroidal immunosuppressive agents ≤14 days prior to Visit 1 e. Topical ocular non-steroidal anti-inflammatory drugs (NSAIDs) ≤14 days prior to Visit 1 f. Topical ophthalmic products, including tear substitutes and over-the-counter (OTC) preparations such as eyelid scrubs, ≤2 hours prior to Visit 1",f,,2025-07-25 16:21:06.083782,2025-07-28 19:38:49.176353,demographics,
248,10,exclusion,17. Be an employee of or immediate family member of an employee (directly related to study conduct) at the investigational site.,f,,2025-07-25 16:21:06.123617,2025-07-28 19:38:49.388908,study_procedures,
249,10,exclusion,"18. Be unsuited for participation in the study for any other reason, per the Investigator’s discretion.",f,,2025-07-25 16:21:06.159572,2025-07-28 19:38:49.317376,study_procedures,
250,10,exclusion,"19. Have recent history (≤6 months) of blepharitis defined by symptoms of routine sticky, crusty or red eyes upon waking.",f,,2025-07-25 16:21:06.198406,2025-07-28 19:38:49.461279,laboratory,
5,11,exclusion,"2. History of symptomatic kidney stones within the past 6 months, nephrectomy, and/or renal transplant.",f,"{""field"": ""condition"", ""value"": ""kidney stones"", ""operator"": ""equals""}",2025-04-01 19:30:18.678807,2025-07-22 19:16:44.201729,medical,
7,11,exclusion,5. Hemoglobin < 10 g/dL (males) or < 9 g/dL (females) at Screening.,f,"{""test"": ""hemoglobin"", ""field"": ""lab_value"", ""value"": 10, ""operator"": ""greater_than""}",2025-04-01 19:30:57.96791,2025-07-22 19:16:47.975766,laboratory,
8,11,inclusion,1. Male or female participants ≥ 18 to ≤ 85 years of age at the time of signing the informed consent form (ICF).,t,"{""unit"": ""years"", ""field"": ""age"", ""value"": [18, 85], ""operator"": ""between""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.871317,demographic,
9,11,inclusion,"2. Participants that have documented medical records stating history of gout. If no documented medical history of gout, delegated site personnel should complete the American College Rheumatology/ European Alliance of Associations for
   Rheumatology gout classification criteria calculator to confirm gout diagnosis.",t,"{""field"": ""diagnosis"", ""value"": ""gout"", ""operator"": ""equals""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:24.580448,medical,
10,11,inclusion,3. Must have had an occurrence of ≥ 2 self-reported gout flares in the last 12 months.,t,"{""field"": ""condition_count"", ""value"": 2, ""operator"": ""greater_than_or_equal"", ""condition"": ""gout flares""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:27.008769,medical,
11,11,inclusion,4. Body weight must be ≥ 50 kg and body mass index between ≥ 18 to ≤ 45 kg/m2.,t,"{""field"": ""bmi"", ""value"": 18.5, ""operator"": ""greater_than_or_equal""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:28.672301,biometric,
12,11,inclusion,5. Male or female participants. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.,f,"{""text"": ""5. Male or female participants. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.146201,other,
13,11,inclusion,"6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.",f,"{""text"": ""6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:20.920015,other,
14,11,inclusion,7. Participants must meet one of the following criteria: a. ULT-naïve participants OR b. Participants entering the study on ULT are willing to washout for a minimum of 10 days before the first IP administration on Day 1.,t,"{""text"": ""7. Participants must meet one of the following criteria: a. ULT-naïve participants OR b. Participants entering the study on ULT are willing to washout for a minimum of 10 days before the first IP administration on Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:37.177695,other,
15,11,inclusion,"8. Participant meets one of the following criteria at Screening: a. If not currently taking an approved ULT, participant must have an sUA value ≥ 7.0 mg/dL (416 µmol/L) OR b. If entering the study on ULT treatment, participant must 
  have an sUA value > 6.0 mg/dL (357 µmol/L).",f,"{""text"": ""8. Participant meets one of the following criteria at Screening: a. If not currently taking an approved ULT, participant must have an sUA value ≥ 7.0 mg/dL (416 µmol/L) OR b. If entering the study on ULT treatment, participant must \n  have an sUA value > 6.0 mg/dL (357 µmol/L)."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.41381,other,
16,11,inclusion,9. Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min by Cockcroft-Gault formula.,f,"{""text"": ""9. Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min by Cockcroft-Gault formula."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.35879,other,
17,11,inclusion,10. Participants taking concomitant medications must be on a stable dose from 4 weeks before Day 1 and agree to maintain the stable dose through to the Final Follow-Up Visit.,f,"{""text"": ""10. Participants taking concomitant medications must be on a stable dose from 4 weeks before Day 1 and agree to maintain the stable dose through to the Final Follow-Up Visit."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.079283,other,
18,11,inclusion,11. Participants previously prescribed pegloticase or rasburicase must have stopped taking these medications for at least 90 days before Day 1.,f,"{""text"": ""11. Participants previously prescribed pegloticase or rasburicase must have stopped taking these medications for at least 90 days before Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.488142,other,
19,11,inclusion,12. Must be free of any clinically significant disease that would interfere with study evaluations or procedures as per the Investigator's judgment.,f,"{""text"": ""12. Must be free of any clinically significant disease that would interfere with study evaluations or procedures as per the Investigator's judgment."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.802947,other,
20,11,exclusion,1. A history of clinically significant disorders or presenting with signs or symptoms of clinically significant disorders that are not well-controlled as per the Investigator's judgment.,f,"{""text"": ""1. A history of clinically significant disorders or presenting with signs or symptoms of clinically significant disorders that are not well-controlled as per the Investigator's judgment."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:55.258747,other,
22,11,exclusion,3. History of xanthinuria.,f,"{""text"": ""3. History of xanthinuria."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:58.626327,other,
23,11,exclusion,4. History of tumor lysis syndrome or Lesch-Nyhan syndrome.,f,"{""text"": ""4. History of tumor lysis syndrome or Lesch-Nyhan syndrome."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:57.778302,other,
25,11,exclusion,"6. Alanine aminotransferase or aspartate aminotransferase > 2.0 × ULN, total bilirubin > 3 mg/dL, and/or international normalized ratio > 1.7 (not on anti-coagulant therapy) at Screening.",f,"{""text"": ""6. Alanine aminotransferase or aspartate aminotransferase > 2.0 × ULN, total bilirubin > 3 mg/dL, and/or international normalized ratio > 1.7 (not on anti-coagulant therapy) at Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:59.62731,other,
26,11,exclusion,"7. Participants that have moderately impaired hepatic function (Child-Pugh Class B) or advanced hepatic dysfunction (Child-Pugh Class C), or participants that are recipients of a liver transplant.",f,"{""text"": ""7. Participants that have moderately impaired hepatic function (Child-Pugh Class B) or advanced hepatic dysfunction (Child-Pugh Class C), or participants that are recipients of a liver transplant."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:02.272186,other,
27,11,exclusion,8. Positive serology to human immunodeficiency virus ([HIV]; HIV1 and HIV2) with a confirmatory positive HIV assay and/or hepatitis C virus (HCV) antibodies with a confirmatory positive HCV RNA and/or hepatitis B surface antigen.,f,"{""text"": ""8. Positive serology to human immunodeficiency virus ([HIV]; HIV1 and HIV2) with a confirmatory positive HIV assay and/or hepatitis C virus (HCV) antibodies with a confirmatory positive HCV RNA and/or hepatitis B surface antigen."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:02.949986,other,
28,11,exclusion,"9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been successfully treated. Participants with a history of other malignancies that have been treated with curative intent at least 3 years 
  before Screening with no recurrence may also be eligible if approved by the Sponsor Medical Monitor (or designee).",f,"{""text"": ""9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been successfully treated. Participants with a history of other malignancies that have been treated with curative intent at least 3 years \n  before Screening with no recurrence may also be eligible if approved by the Sponsor Medical Monitor (or designee)."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:06.367464,other,
29,11,exclusion,"10. History of complete heart block, QTc prolongation, Torsades de pointes, or any family history of congenital QT interval prolongation syndrome.",f,"{""text"": ""10. History of complete heart block, QTc prolongation, Torsades de pointes, or any family history of congenital QT interval prolongation syndrome."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:08.030449,other,
30,11,exclusion,"11. History within 6 months before Screening and/or presence of substance use disorders including alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.",f,"{""text"": ""11. History within 6 months before Screening and/or presence of substance use disorders including alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:11.370161,medical,
31,11,exclusion,"12. History of severe allergic reaction (e.g., anaphylaxis) to a food, drug, chemical, or natural substance.",t,"{""text"": ""12. History of severe allergic reaction (e.g., anaphylaxis) to a food, drug, chemical, or natural substance."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:56.824987,other,
32,11,exclusion,"13. Uncontrolled hypertension (e.g., systolic pressure > 160 mm Hg, or diastolic pressure > 95 mm Hg on repeated measures).",f,"{""field"": ""diagnosis"", ""value"": ""hypertension""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:13.813089,other,
33,11,exclusion,14. QT corrected for heart rate according to Fridericia (QTcF) interval > 450 msec (males) or > 480 msec (females) at Screening.,f,"{""text"": ""14. QT corrected for heart rate according to Fridericia (QTcF) interval > 450 msec (males) or > 480 msec (females) at Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:15.885729,other,
34,11,exclusion,15. Any use of concomitant medications that have a moderate or high risk of prolonging the QT/QTc interval within 14 days before Day 1.,f,"{""text"": ""15. Any use of concomitant medications that have a moderate or high risk of prolonging the QT/QTc interval within 14 days before Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.001419,other,
35,11,exclusion,16. Participants requiring long-term use of high-dose salicylates (> 1g/day) will be excluded.,f,"{""text"": ""16. Participants requiring long-term use of high-dose salicylates (> 1g/day) will be excluded."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.931647,other,
36,11,exclusion,17. Participants requiring or taking warfarin will be excluded.,f,"{""text"": ""17. Participants requiring or taking warfarin will be excluded."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.868446,other,
37,11,exclusion,18. Received any vaccinations (including coronavirus disease-2019 and influenza) within 14 days before dosing on Day 1.,f,"{""text"": ""18. Received any vaccinations (including coronavirus disease-2019 and influenza) within 14 days before dosing on Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.067268,other,
38,11,exclusion,19. Received pegloticase or rasburicase within the 3 months before Screening.,f,"{""text"": ""19. Received pegloticase or rasburicase within the 3 months before Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.348426,other,
39,11,exclusion,"20. Previously dosed with AR882 or previously received an IP, investigational biological agent, or investigational device within 3 months or 5 half-lives of the IP, whichever is longer.",f,"{""text"": ""20. Previously dosed with AR882 or previously received an IP, investigational biological agent, or investigational device within 3 months or 5 half-lives of the IP, whichever is longer."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.720971,demographic,
40,11,exclusion,21. Safety laboratory abnormality values considered clinically significant by the Investigator.,f,"{""text"": ""21. Safety laboratory abnormality values considered clinically significant by the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.137779,laboratory,
41,11,exclusion,"22. Positive test for drugs of abuse (cocaine, methamphetamine, amphetamine, benzodiazepines, methadone, barbiturates, or opiates) at Screening. Participants with positive test(s) for amphetamines, barbiturates, benzodiazepines, or 
  opiates who present documentation of a valid prescription for the respective drug will be permitted if the prescription is deemed acceptable by the Investigator.",f,"{""text"": ""22. Positive test for drugs of abuse (cocaine, methamphetamine, amphetamine, benzodiazepines, methadone, barbiturates, or opiates) at Screening. Participants with positive test(s) for amphetamines, barbiturates, benzodiazepines, or \n  opiates who present documentation of a valid prescription for the respective drug will be permitted if the prescription is deemed acceptable by the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.216474,laboratory,
42,11,exclusion,23. Inadequate venous access or unsuitable veins for repeated venipuncture in the opinion of the Investigator.,f,"{""text"": ""23. Inadequate venous access or unsuitable veins for repeated venipuncture in the opinion of the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.280374,other,
43,11,exclusion,24. Any acute illness within 1 week of Day 1 or active infection within 2 weeks of Day 1.,f,"{""text"": ""24. Any acute illness within 1 week of Day 1 or active infection within 2 weeks of Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.436126,other,
44,11,exclusion,25. Had major surgery within 3 months of Day 1.,f,"{""text"": ""25. Had major surgery within 3 months of Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.290993,other,
45,11,exclusion,"26. Donated whole blood within 8 weeks before Day 1 or donated plasma within 4 weeks before Screening. Participants must agree to refrain from donation of blood, fluids, and other tissue throughout the treatment period until 12 weeks
   after receiving the last dose of IP.",f,"{""text"": ""26. Donated whole blood within 8 weeks before Day 1 or donated plasma within 4 weeks before Screening. Participants must agree to refrain from donation of blood, fluids, and other tissue throughout the treatment period until 12 weeks\n   after receiving the last dose of IP."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.787814,other,
46,11,exclusion,27. Clinically relevant intolerance or allergy to AR882 or is known or suspected to have hypersensitivity to benzbromarone and/or any ingredient in the study treatments.,f,"{""text"": ""27. Clinically relevant intolerance or allergy to AR882 or is known or suspected to have hypersensitivity to benzbromarone and/or any ingredient in the study treatments."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.661797,other,
47,11,exclusion,"28. Is in a situation or with a condition that, in the opinion of the Investigator, may interfere with optimal participation in the study.",f,"{""text"": ""28. Is in a situation or with a condition that, in the opinion of the Investigator, may interfere with optimal participation in the study."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.577275,other,
48,11,exclusion,29. Is involved in other clinical studies throughout the period of this study.,f,"{""text"": ""29. Is involved in other clinical studies throughout the period of this study."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.508036,other,
49,11,exclusion,30. Is unable or unwilling to comply with study restrictions.,f,"{""text"": ""30. Is unable or unwilling to comply with study restrictions."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.655299,other,
251,12,inclusion,1. Male and female subjects aged ≥ 50 years.,t,,2025-07-28 19:38:39.656681,2025-07-28 19:38:39.656681,demographics,
252,12,inclusion,2. Established diagnosis of T2DM for at least 6 months prior to Screening AND an A1C ≥ 7.2% but ≤ 10.0% at Screening.,t,,2025-07-28 19:38:39.706686,2025-07-28 19:38:39.706686,laboratory,
253,12,inclusion,"3. On a stable dose of at least one and up to three of the following glucose-lowering agents: Metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, thiazolidinedione, insulin secretagogue, oral or injected GLP-1 receptor agonists, glucosidase inhibitor, or pramlintide (injected insulin is excluded) for a minimum of 3 months prior to Screening.",t,,2025-07-28 19:38:39.746513,2025-07-28 19:38:39.746513,demographics,
254,12,inclusion,"4. Body mass index (BMI) of ≤ 28 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.",t,,2025-07-28 19:38:39.779808,2025-07-28 19:38:39.779808,disease_specific,
255,12,inclusion,5. Renal function – eGFR ≥ 30 ml/min.,t,,2025-07-28 19:38:39.815643,2025-07-28 19:38:39.815643,laboratory,
256,12,inclusion,6. Females of childbearing potential must:,t,,2025-07-28 19:38:39.856198,2025-07-28 19:38:39.856198,demographics,
257,12,inclusion,a. Have a negative serum pregnancy test result at Screening.,t,,2025-07-28 19:38:39.892492,2025-07-28 19:38:39.892492,laboratory,
258,12,inclusion,"b. Agree to avoid becoming pregnant while receiving IP for at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP.",t,,2025-07-28 19:38:39.929082,2025-07-28 19:38:39.929082,laboratory,
259,12,inclusion,"c. Agree to use an acceptable method of contraception at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP. Acceptable methods of contraception are hormonal contraception (contraceptive pill or injection) PLUS an additional barrier method of contraception such as a diaphragm, condom, sponge, or spermicide.",t,,2025-07-28 19:38:39.976944,2025-07-28 19:38:39.976944,demographics,
260,12,inclusion,"d. In the absence of hormonal contraception, double-barrier methods must be used which include a combination of any two of the following: diaphragm, condom, copper intrauterine device, sponge, or spermicide, and must be used for at least 30 days prior to administration of IP, during the entire study, and for 30 days following their last dose of IP.",t,,2025-07-28 19:38:40.018806,2025-07-28 19:38:40.018806,demographics,
261,12,inclusion,"e. Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject’s preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.",t,,2025-07-28 19:38:40.053469,2025-07-28 19:38:40.053469,demographics,
262,12,inclusion,f. Females who are not of childbearing potential are defined as:,t,,2025-07-28 19:38:40.087227,2025-07-28 19:38:40.087227,demographics,
263,12,inclusion,i. Postmenopausal (defined as at least 12 months with no menses in women ≥ 45 years of age); OR,t,,2025-07-28 19:38:40.125281,2025-07-28 19:38:40.125281,demographics,
264,12,inclusion,"ii. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR",t,,2025-07-28 19:38:40.158955,2025-07-28 19:38:40.158955,laboratory,
265,12,inclusion,iii. Have a congenital or acquired condition that prevents childbearing.,t,,2025-07-28 19:38:40.19239,2025-07-28 19:38:40.19239,disease_specific,
266,12,exclusion,1. Type 1 diabetes by history.,t,,2025-07-28 19:38:40.230928,2025-07-28 19:38:40.230928,disease_specific,
267,12,exclusion,"2. Diabetes attributable to other secondary causes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).",t,,2025-07-28 19:38:40.272318,2025-07-28 19:38:40.272318,disease_specific,
268,12,exclusion,3. Treatment involving injected insulin within 3 months prior to Visit 1.,t,,2025-07-28 19:38:40.309383,2025-07-28 19:38:40.309383,medical_history,
269,12,exclusion,4. A history of > 2 episodes of severe hypoglycemia within 6 months prior to Screening.,t,,2025-07-28 19:38:40.351507,2025-07-28 19:38:40.351507,disease_specific,
270,12,exclusion,5. A history of hypoglycemic unawareness.,t,,2025-07-28 19:38:40.385079,2025-07-28 19:38:40.385079,medical_history,
271,12,exclusion,"6. A history of unstable angina or myocardial infarction within 6 months prior to Screening, New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure (CHF), valvular heart disease, ventricular cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke, or transient ischemic attack (TIA) within 6 months prior to Screening.",t,,2025-07-28 19:38:40.424705,2025-07-28 19:38:40.424705,laboratory,
272,12,exclusion,7. A history of uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg. A single repeat measurement will be permitted.,t,,2025-07-28 19:38:40.458257,2025-07-28 19:38:40.458257,laboratory,
273,12,exclusion,8. Renal dysfunction: eGFR < 30 mL/min.,t,,2025-07-28 19:38:40.497043,2025-07-28 19:38:40.497043,laboratory,
274,12,exclusion,9. A history of or active proliferative retinopathy requiring treatment.,t,,2025-07-28 19:38:40.534626,2025-07-28 19:38:40.534626,medical_history,
275,12,exclusion,"10. Psychiatric disorders that, per Investigator judgment, may have impact on the safety of the subject or interfere with subject’s participation or compliance in the study.",t,,2025-07-28 19:38:40.568026,2025-07-28 19:38:40.568026,disease_specific,
276,12,exclusion,11. Laboratory abnormalities at Screening including:,t,,2025-07-28 19:38:40.606734,2025-07-28 19:38:40.606734,laboratory,
277,12,exclusion,a. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the upper limit of normal; a single repeat test is allowable.,t,,2025-07-28 19:38:40.642784,2025-07-28 19:38:40.642784,laboratory,
278,12,exclusion,"b. Elevated liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)) > 3X the upper limit of normal; a single repeat test is allowable.",t,,2025-07-28 19:38:40.685664,2025-07-28 19:38:40.685664,laboratory,
279,12,exclusion,c. Very elevated fasting triglyceride levels (> 600 mg/dL); a single repeat test is allowable.,t,,2025-07-28 19:38:40.730193,2025-07-28 19:38:40.730193,laboratory,
280,12,exclusion,d. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.,t,,2025-07-28 19:38:40.769582,2025-07-28 19:38:40.769582,medications,
281,12,exclusion,"12. Positive history of active liver disease (other than non-alcoholic hepatic steatosis), primary biliary cirrhosis, or active symptomatic gallbladder disease.",t,,2025-07-28 19:38:40.822137,2025-07-28 19:38:40.822137,laboratory,
282,12,exclusion,"13. Positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus ribonucleic acid (RNA).",t,,2025-07-28 19:38:40.86443,2025-07-28 19:38:40.86443,general,
283,12,exclusion,14. Patient has active or history of neoplastic disease (except for adequately treated non-invasive basal cell and/or squamous cell carcinoma or carcinoma in situ of the cervix) within the past 5 years prior to baseline.,t,,2025-07-28 19:38:40.908447,2025-07-28 19:38:40.908447,laboratory,
284,12,exclusion,15. Use of the following medications:,t,,2025-07-28 19:38:40.944506,2025-07-28 19:38:40.944506,medications,
285,12,exclusion,a. History of use of any injectable insulin (greater than 7 days) within 6 months prior to Screening.,t,,2025-07-28 19:38:40.981189,2025-07-28 19:38:40.981189,medical_history,
286,12,exclusion,b. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.,t,,2025-07-28 19:38:41.020404,2025-07-28 19:38:41.020404,laboratory,
287,12,exclusion,"c. Use of oral, intravenous, or intramuscular steroids for one month prior to enrollment. Intra-articular and/or topical corticosteroids are not considered systemic.",t,,2025-07-28 19:38:41.061288,2025-07-28 19:38:41.061288,medical_history,
288,12,exclusion,"d. Concurrent use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and immunosuppressive or immunomodulating agents. Inhaled nasal steroids are permissible.",t,,2025-07-28 19:38:41.096105,2025-07-28 19:38:41.096105,demographics,
289,12,exclusion,16. Known allergy to soy.,t,,2025-07-28 19:38:41.13665,2025-07-28 19:38:41.13665,safety,
290,12,exclusion,"17. Involvement in a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide) within 3 months prior to Screening.",t,,2025-07-28 19:38:41.171427,2025-07-28 19:38:41.171427,medical_history,
291,12,exclusion,18. Prior bariatric surgery.,t,,2025-07-28 19:38:41.206987,2025-07-28 19:38:41.206987,medical_history,
292,12,exclusion,19. Subject is pregnant or breast-feeding.,t,,2025-07-28 19:38:41.242758,2025-07-28 19:38:41.242758,laboratory,
293,12,exclusion,20. Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by > 3 drinks per day or > 14 drinks per week or binge drinking) at Screening. Occasional intermittent use of cannabinoid products will be allowed provided that no cannabinoid products have been used during the 1 week prior to each visit.,t,,2025-07-28 19:38:41.277434,2025-07-28 19:38:41.277434,disease_specific,
294,12,exclusion,21. Weight loss preparations either approved and marketed or used in OTC preparations except for GLP-1 used in the treatment of underlying diabetes.,t,,2025-07-28 19:38:41.315216,2025-07-28 19:38:41.315216,laboratory,
295,12,exclusion,22. Any condition or other factor (at the Investigator’s discretion) that is deemed unsuitable for subject enrollment into the study.,t,,2025-07-28 19:38:41.365791,2025-07-28 19:38:41.365791,disease_specific,
50,15,inclusion,Are adult male and female subjects ≥18 years of age,t,"{""text"": ""Are adult male and female subjects ≥18 years of age"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235,demographic,
51,15,inclusion,"Have a body mass index between 18 and 45 kg/m2, inclusive at Screening",t,"{""text"": ""Have a body mass index between 18 and 45 kg/m2, inclusive at Screening"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
52,15,inclusion,"Meet Rome IV Criteria for IBS-D by subject self-report of recurrent abdominal pain that is associated with ≥2 of the following over the last ≥6 months, with frequency of at least 1 day per week over the last 3 months (on average) before enrollment: Related to defecation; Associated with a change in frequency of stool; and/or Associated with a change in form (appearance of stool)",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235,demographic,
53,15,inclusion,"Based on Investigator interview of subject’s symptoms over the last 3 months, have ≥25% of bowel movements (BMs) with Bristol Stool Scale (BSS) Type 6 or 7 (loose or watery stools) and <25% of BMs with BSS Type 1 or 2 (lumpy or hard stools) per the Rome IV Criteria for IBS-D",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
54,15,inclusion,"In the opinion of the Investigator, are on a stable diet for ≥4 weeks prior to Screening and are not planning to change lifestyle, exercise, and/or diet that may impact symptoms of IBS-D during study participation",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
55,15,inclusion,Have a fecal calprotectin ≤ 100 mcg/g at the Screening Visit or Visit 2,t,"{""text"": ""Have a fecal calprotectin ≤ 100 mcg/g at the Screening Visit or Visit 2"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
56,15,inclusion,Have a serum tTG-IgA (tissue transglutaminase immunoglobulin A) ≤4.99 FLU at the Screening Visit,t,"{""text"": ""Have a serum tTG-IgA (tissue transglutaminase immunoglobulin A) ≤4.99 FLU at the Screening Visit"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
57,15,inclusion,"Have undergone a colonoscopy examination within the designated time interval prior to randomization, if they meet any of the following criteria: Average risk, based on US Preventive Services Task Force Recommendation Statement for screening of colorectal cancer, with age ≥45 years (colonoscopy within 10 years or negative test results on Cologuard within 3 years); Personal history of completely removed adenomatous colorectal polyps (colonoscopy within 5 years for polyps >1 cm, within 10 years for polyps <1 cm); History of colorectal cancer or adenomatous polyps in a first-degree relative before age 60 (colonoscopy within 5 years); or History of colorectal cancer or adenomatous polyps in ≥2 first-degree relatives at any age, or family history of hereditary colorectal cancer or polyposis (colonoscopy within 5 years)",t,"{""text"": ""Have undergone a colonoscopy examination within the designated time interval prior to randomization, if they meet any of the following criteria: Average risk, based on US Preventive Services Task Force Recommendation Statement for screening of colorectal cancer, with age ≥45 years (colonoscopy within 10 years or negative test results on Cologuard within 3 years); Personal history of completely removed adenomatous colorectal polyps (colonoscopy within 5 years for polyps >1 cm, within 10 years for polyps <1 cm); History of colorectal cancer or adenomatous polyps in a first-degree relative before age 60 (colonoscopy within 5 years); or History of colorectal cancer or adenomatous polyps in ≥2 first-degree relatives at any age, or family history of hereditary colorectal cancer or polyposis (colonoscopy within 5 years)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235,demographic,
58,15,inclusion,"Female subjects of childbearing potential must have a negative pregnancy test result at the Screening Visit, Visit 2, and Visit 3 (prior to randomization and the first dose of study drug); must not be pregnant, lactating, or planning a pregnancy during the study; and agree to use 2 medically accepted, effective methods of birth control from Day -14 until 6 months after the last dose of study drug",t,"{""text"": ""Female subjects of childbearing potential must have a negative pregnancy test result at the Screening Visit, Visit 2, and Visit 3 (prior to randomization and the first dose of study drug); must not be pregnant, lactating, or planning a pregnancy during the study; and agree to use 2 medically accepted, effective methods of birth control from Day -14 until 6 months after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,laboratory,
59,15,inclusion,"Female subjects of non-childbearing potential with male partners must either be surgically sterile (full hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit), or postmenopausal (defined as no menses for 12 months without an alternative medical cause and should have a high follicle-stimulating hormone level in the postmenopausal range at Screening, based on the central laboratory’s range)",t,"{""text"": ""Female subjects of non-childbearing potential with male partners must either be surgically sterile (full hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit), or postmenopausal (defined as no menses for 12 months without an alternative medical cause and should have a high follicle-stimulating hormone level in the postmenopausal range at Screening, based on the central laboratory’s range)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,laboratory,
60,15,inclusion,"Male subjects with female partners of childbearing potential must be willing and agree to use a single effective method of birth control (eg, condom with spermicide) during their participation in the study and for 90 days after the last dose of study drug",t,"{""text"": ""Male subjects with female partners of childbearing potential must be willing and agree to use a single effective method of birth control (eg, condom with spermicide) during their participation in the study and for 90 days after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
61,15,inclusion,Must agree to abstain from sperm donation through 90 days after the last dose of study drug or egg donation through 6 months after the last dose of study drug,t,"{""text"": ""Must agree to abstain from sperm donation through 90 days after the last dose of study drug or egg donation through 6 months after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
62,15,inclusion,"Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, including those to treat IBS-D (as specified in the Protocol) and provide written informed consent according to institutional and regulatory guidelines",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
63,15,exclusion,"Have a diagnosis or suspected diagnosis of non-diarrhea predominant IBS (eg, IBS with a subtype of constipation, IBS with mixed or alternating bowel habits, un-subtyped IBS) or functional constipation by the Rome IV Criteria",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235,medical,
64,15,exclusion,"Non-infectious chronic lower gastrointestinal conditions including a history of or current inflammatory bowel disease (ie, Crohn’s disease, ulcerative colitis, indeterminate colitis), recurrent diverticulitis, microscopic colitis, lymphocytic colitis, celiac disease, non-celiac gluten sensitivity and non-compliant on a gluten-free diet, untreated lactose intolerance, carcinoid syndrome, Lynch syndrome, or familial polyposis, intestinal obstruction, stricture, toxic megacolon, solitary rectal ulcer syndrome, GI perforation, intra-abdominal or pelvic adhesions, ischemic colitis, radiation proctitis, chronic enteritis, non-infectious colitis, or impaired intestinal circulation (eg, aortoiliac disease)",t,"{""text"": ""Non-infectious chronic lower gastrointestinal conditions including a history of or current inflammatory bowel disease (ie, Crohn’s disease, ulcerative colitis, indeterminate colitis), recurrent diverticulitis, microscopic colitis, lymphocytic colitis, celiac disease, non-celiac gluten sensitivity and non-compliant on a gluten-free diet, untreated lactose intolerance, carcinoid syndrome, Lynch syndrome, or familial polyposis, intestinal obstruction, stricture, toxic megacolon, solitary rectal ulcer syndrome, GI perforation, intra-abdominal or pelvic adhesions, ischemic colitis, radiation proctitis, chronic enteritis, non-infectious colitis, or impaired intestinal circulation (eg, aortoiliac disease)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,laboratory,
65,15,exclusion,"Infectious lower gastrointestinal conditions requiring antibiotics or microbiome therapy; any microbiologically documented acute lower gastrointestinal colitis or enteritis requiring antibiotic treatment including successfully treated Clostridioides difficile colitis within 3 months prior to Screening, or a history of recurrent C. difficile colitis at any time in the past",t,"{""text"": ""Infectious lower gastrointestinal conditions requiring antibiotics or microbiome therapy; any microbiologically documented acute lower gastrointestinal colitis or enteritis requiring antibiotic treatment including successfully treated Clostridioides difficile colitis within 3 months prior to Screening, or a history of recurrent C. difficile colitis at any time in the past"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,laboratory,
66,15,exclusion,Have a known family history of inflammatory bowel disease in at least 1 first-degree relative,t,"{""text"": ""Have a known family history of inflammatory bowel disease in at least 1 first-degree relative"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
67,15,exclusion,"Have a known history of a pelvic floor disorder associated with constipation (unless successful treatment has been documented by a normal balloon expulsion test or anorectal manometry), refractory constipation not responsive to standard medical therapy, fecal impaction that required hospitalization, cathartic colon, and/or active proctological condition",t,"{""text"": ""Have a known history of a pelvic floor disorder associated with constipation (unless successful treatment has been documented by a normal balloon expulsion test or anorectal manometry), refractory constipation not responsive to standard medical therapy, fecal impaction that required hospitalization, cathartic colon, and/or active proctological condition"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,laboratory,
68,15,exclusion,"Have a history of or current non-IBS chronic condition(s) with ongoing symptoms associated with abdominal pain or GI discomfort (eg, gastroparesis, functional dyspepsia, uncontrolled)",t,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483,other,
192,18,inclusion,I01: Aged 18 to 45 years on the day of the first study intervention administration a,t,,2025-07-24 22:04:50.071112,2025-07-24 22:04:50.071112,demographics,
193,18,inclusion,"I02: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator",f,,2025-07-24 22:04:50.111165,2025-07-25 16:15:03.466246,laboratory,
194,18,inclusion,"I03: Clinical diagnosis of moderate or severe facial acne vulgaris with: • IGA score of Moderate or Severe (grade 3 or grade 4 on the 5-grade IGA scale) AND • ≥ 25 non-inflammatory lesions (ie, open and closed comedones) AND • ≥ 20 inflammatory lesions (ie, papules and pustules) AND • ≤ 2 nodulocystic lesions (ie, nodules and cysts)",f,,2025-07-24 22:04:50.147237,2025-07-25 16:15:06.522075,disease_specific,
195,18,inclusion,"I04: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions appliesb: • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR • Is of childbearing potential and agrees to use an effective contraceptive methodc or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before the first study intervention administration",f,,2025-07-24 22:04:50.184869,2025-07-25 16:15:08.861956,demographics,
196,18,inclusion,I05: Informed consent form has been signed and dateda,f,,2025-07-24 22:04:50.222203,2025-07-25 16:15:10.83772,study_procedures,
197,18,inclusion,I06: Able to attend all scheduled visits and to comply with all study procedures,f,,2025-07-24 22:04:50.258419,2025-07-25 16:15:12.719822,study_procedures,
198,18,inclusion,I07: Refrain from use of any other acne treatments for the duration of the study (pre-specified non-medicated cleansers and sunscreen will be allowedb),t,,2025-07-24 22:04:50.296129,2025-07-24 22:04:50.296129,disease_specific,
199,18,exclusion,"E01: Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)",f,,2025-07-24 22:04:50.331957,2025-07-25 16:15:34.46955,laboratory,
200,18,exclusion,"E02: Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol [PEG], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substancesc; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID-19) vaccine",t,,2025-07-24 22:04:50.37548,2025-07-24 22:04:50.37548,disease_specific,
201,18,exclusion,E03: Previous history of myocarditis and/or pericarditis and/or myopericarditis,t,,2025-07-24 22:04:50.411584,2025-07-24 22:04:50.411584,medical_history,
202,18,exclusion,"E04: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion",f,,2025-07-24 22:04:50.454407,2025-07-25 16:15:38.73785,demographics,
203,18,exclusion,"E05: Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating intramuscular injection based on investigator’s judgement",f,,2025-07-24 22:04:50.492513,2025-07-25 16:15:39.940987,laboratory,
204,18,exclusion,"E06: Active nodulocystic acne, acne conglobate, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica)",f,,2025-07-24 22:04:50.533365,2025-07-25 16:15:42.723176,disease_specific,
205,18,exclusion,"E07: Skin pathology or condition that, in the investigator’s opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapya",f,,2025-07-24 22:04:50.569354,2025-07-25 16:15:48.896278,disease_specific,
206,18,exclusion,"E08: Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator’s opinion (including – but not limited to – actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection",f,,2025-07-24 22:04:50.612172,2025-07-25 16:15:53.926505,disease_specific,
207,18,exclusion,"E09: Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion",f,,2025-07-24 22:04:50.6462,2025-07-25 16:15:55.621465,laboratory,
208,18,exclusion,E10: Start or switch of hormonal contraceptive use within 12 weeks prior to the first study intervention administration or plans to initiate or switch hormonal contraceptive products during the study periodb,t,,2025-07-24 22:04:50.681562,2025-07-24 22:04:50.681562,demographics,
209,18,exclusion,E11: Previous use of oral isotretinoin,f,,2025-07-24 22:04:50.715987,2025-07-25 16:16:00.491716,medical_history,
210,18,exclusion,E12: Use of any acne-affecting treatment without an appropriate washout period. Participants receiving prohibited medications/therapies at Screening Visit will have to observe a washout period of 2 weeks to 24 weeks before enrolment (as specified in the table below) to preserve eligibility in the study.,f,,2025-07-24 22:04:50.75133,2025-07-25 16:16:03.432624,disease_specific,
211,18,exclusion,E13: Receipt of any vaccine (other than the study vaccine) in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine (other than the study vaccine) in the 4 weeks following any study intervention administration,t,,2025-07-24 22:04:50.787221,2025-07-24 22:04:50.787221,laboratory,
212,18,exclusion,E14: Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration,f,,2025-07-24 22:04:50.824435,2025-07-25 16:16:11.712794,laboratory,
213,18,exclusion,E15: Previous vaccination against C. acnes with an investigational vaccine,f,,2025-07-24 22:04:50.86163,2025-07-25 16:16:19.446528,disease_specific,
214,18,exclusion,"E16: Receipt of immune globulins, blood or blood-derived products in the past 3 months",f,,2025-07-24 22:04:50.899743,2025-07-25 16:16:22.509308,laboratory,
215,18,exclusion,"E17: Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus",f,,2025-07-24 22:04:50.95186,2025-07-25 16:16:23.772672,general,
216,18,exclusion,"E18: Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure",f,,2025-07-24 22:04:50.993799,2025-07-25 16:16:26.235845,medications,
217,18,exclusion,E19: Planned participation in strenuous or endurance exercise up to D08 after any study intervention administrationa,f,,2025-07-24 22:04:51.031512,2025-07-25 16:16:28.382396,medications,
218,18,exclusion,"E20: Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily",f,,2025-07-24 22:04:51.070942,2025-07-25 16:16:34.792626,general,
219,18,exclusion,"E21: Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study",f,,2025-07-24 22:04:51.107454,2025-07-25 16:16:35.862099,laboratory,
220,18,exclusion,E22: Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided,f,,2025-07-24 22:04:51.147444,2025-07-25 16:18:29.23077,disease_specific,
221,18,exclusion,"E23: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.",f,,2025-07-24 22:04:51.182615,2025-07-25 16:18:26.975738,demographics,
222,18,exclusion,"E24: Participants with a screening electrocardiogram that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results",f,,2025-07-24 22:04:51.222621,2025-07-25 16:18:31.163224,safety,
223,18,exclusion,E25: Any screening laboratory parameter with laboratory abnormalities that are Grade 2 or above or deemed clinically significant in the opinion of the investigator,f,,2025-07-24 22:04:51.258857,2025-07-25 16:18:32.217357,laboratory,
124,19,inclusion,"Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.",t,"{""text"": ""Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:26.170235,demographic,
125,19,inclusion,"Patient has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated.",t,"{""text"": ""Patient has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
126,19,inclusion,Patient has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).,t,"{""text"": ""Patient has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1)."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
127,19,inclusion,Meet the following requirements: Is a male OR Is a female who is of non-childbearing potential OR Is a female of reproductive potential and agrees to remain abstinent from heterosexual activity or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit.,t,"{""text"": ""Meet the following requirements: Is a male OR Is a female who is of non-childbearing potential OR Is a female of reproductive potential and agrees to remain abstinent from heterosexual activity or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:26.170235,demographic,
128,19,inclusion,Patient voluntarily agrees to participate in the study by giving written informed consent.,t,"{""text"": ""Patient voluntarily agrees to participate in the study by giving written informed consent."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
129,19,inclusion,"Patient is able to read, understand and complete the study questionnaires and diary.",t,"{""text"": ""Patient is able to read, understand and complete the study questionnaires and diary."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
130,19,inclusion,"Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.",t,"{""text"": ""Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
131,19,inclusion,"Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.",t,"{""text"": ""Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
132,19,exclusion,"Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study.",t,"{""text"": ""Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483,other,
107,21,inclusion,Is a male or female ≥18 years of age,t,"{""text"": ""Is a male or female ≥18 years of age"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:36:06.082661,demographic,
108,21,inclusion,"Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria",t,"{""field"": ""diagnosis"", ""value"": ""diabetes""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:45.23562,medical,
109,21,inclusion,Has a current diagnosis of diabetic gastroparesis defined by persistent gastrointestinal symptoms consistent with gastroparesis and documented delayed gastric emptying,f,"{""text"": ""Has a current diagnosis of diabetic gastroparesis defined by persistent gastrointestinal symptoms consistent with gastroparesis and documented delayed gastric emptying"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.533055,medical,
110,21,inclusion,"Has a body mass index between 18 and 49 kg/m2, inclusive, at Screening",t,"{""text"": ""Has a body mass index between 18 and 49 kg/m2, inclusive, at Screening"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:50.18307,other,
111,21,inclusion,"Has an HbA1c level ≤10% at Screening and, in the opinion of the Investigator, has stable, well-controlled blood glucose",f,"{""text"": ""Has an HbA1c level ≤10% at Screening and, in the opinion of the Investigator, has stable, well-controlled blood glucose"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-04-11 13:31:31.327,other,
112,21,inclusion,"If receiving treatment with GLP-1RA, must meet specific criteria regarding the use and tolerance of GLP-1RA",f,"{""text"": ""If receiving treatment with GLP-1RA, must meet specific criteria regarding the use and tolerance of GLP-1RA"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.652486,other,
113,21,inclusion,"Male subjects with female partners of childbearing potential must agree to use 2 medically accepted, effective methods of birth control from Day 1 until 90 days following the final dose of study drug",f,"{""text"": ""Male subjects with female partners of childbearing potential must agree to use 2 medically accepted, effective methods of birth control from Day 1 until 90 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.856684,other,
114,21,inclusion,Male subjects must agree to abstain from sperm donation from Day 1 until 90 days following the final dose of study drug,f,"{""text"": ""Male subjects must agree to abstain from sperm donation from Day 1 until 90 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.073778,other,
115,21,inclusion,"Female subjects with male partners must be surgically sterile, postmenopausal, or agree to use 2 medically accepted, effective methods of birth control from Day -14 until 60 days following the final dose of study drug",f,"{""text"": ""Female subjects with male partners must be surgically sterile, postmenopausal, or agree to use 2 medically accepted, effective methods of birth control from Day -14 until 60 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.929972,other,
116,21,inclusion,Is willing and able to refrain from pramlintide from Screening until End of Treatment (EOT),f,"{""text"": ""Is willing and able to refrain from pramlintide from Screening until End of Treatment (EOT)"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.212675,other,
117,21,inclusion,"Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, and provide written informed consent",f,"{""text"": ""Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, and provide written informed consent"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.999498,other,
118,21,exclusion,Has a known primary cause of gastroparesis other than diabetes,f,"{""field"": ""diagnosis"", ""value"": ""diabetes""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.146186,other,
119,21,exclusion,Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition,f,"{""text"": ""Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.279517,other,
120,21,exclusion,"Has a history of, or current, clinically significant arrhythmias",f,"{""text"": ""Has a history of, or current, clinically significant arrhythmias"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.347702,other,
121,21,exclusion,"Has evidence or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease",f,"{""text"": ""Has evidence or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.580323,laboratory,
122,21,exclusion,Has clinically significant abdominal surgical conditions or cancer that might interfere with the study drug,f,"{""text"": ""Has clinically significant abdominal surgical conditions or cancer that might interfere with the study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.492408,other,
123,21,exclusion,"Any condition that, in the Investigator’s opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug",f,"{""text"": ""Any condition that, in the Investigator’s opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.421299,other,
81,47,inclusion,Male and female participants ≥50 years of age at the time of consent.,t,"{""text"": ""Male and female participants ≥50 years of age at the time of consent."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:26.170235,demographic,
82,47,inclusion,"Participants who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADLs).",f,"{""text"": ""Participants who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADLs)."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:11:59.365007,other,
83,47,inclusion,"Participants who are willing and able to comply with scheduled visits, laboratory tests, lifestyle considerations, and other study procedures, including daily completion of the e-diary for 7 days after each study vaccination.",f,"{""text"": ""Participants who are willing and able to comply with scheduled visits, laboratory tests, lifestyle considerations, and other study procedures, including daily completion of the e-diary for 7 days after each study vaccination."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:00.18981,laboratory,
84,47,inclusion,"Participants who are determined by medical history, physical examination (if required), and clinical judgement of the investigator to be eligible for inclusion in the study.",f,"{""text"": ""Participants who are determined by medical history, physical examination (if required), and clinical judgement of the investigator to be eligible for inclusion in the study."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:03.178751,other,
85,47,inclusion,"Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.",f,"{""text"": ""Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:04.367552,other,
86,47,exclusion,Current clinically suspected or polymerase chain reaction (PCR)–confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months.,t,"{""text"": ""Current clinically suspected or polymerase chain reaction (PCR)–confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483,other,
87,47,exclusion,"History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.",t,"{""text"": ""History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483,other,
88,47,exclusion,Prior history of any subtype of Guillain Barré syndrome of any etiology.,f,"{""text"": ""Prior history of any subtype of Guillain Barré syndrome of any etiology."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:10.870189,other,
89,47,exclusion,"Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator’s opinion, excludes the participant from participating in the study.",f,"{""text"": ""Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator’s opinion, excludes the participant from participating in the study."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:11.938941,demographic,
90,47,exclusion,"Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.",f,"{""text"": ""Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:15.188955,laboratory,
91,47,exclusion,Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s).,f,"{""text"": ""Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s)."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:19.820228,other,
92,47,exclusion,"Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation.",t,"{""text"": ""Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483,other,
93,47,exclusion,"Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine during study participation.",t,"{""text"": ""Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine during study participation."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483,other,
1,49,inclusion,"BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 plus a documented history of or currently being treated for at least one of the following co-morbidities: hypertension, dyslipidaemia or obstructive sleep apnoea",t,"{""field"": ""diagnosis"", ""value"": ""hypertension""}",2025-04-01 18:41:12.205758,2025-04-11 13:31:10.984483,biometric,
